EFFECTS OF TYPE 2 DIABETES AND ITS IMPACT ON THE RISK OF DEVELOPING ARDS IN PATIENTS WITH LUNG CANCER POSTOPERATIVELY AND ITS PROGNOSIS

AJ CHAUDHARY; S IQBAL; N IQBAL; S KUMAR; . AROONA; MS NADEEM

doi:10.54112/bcsrj.v2024i1.875

Authors

AJ CHAUDHARY Department of Internal Medicine, DMC Sinai Grace Hospital, USA
S IQBAL Department of Internal Medicine, DMC Sinai Grace Hospital, USA
N IQBAL Department of Internal Medicine, MD Health Center, Lahore
S KUMAR Department of Medicine, Liaquat National Medical College, Karachi
. AROONA Department of Internal Medicine, SIUT Karachi, Pakistan
MS NADEEM Department of Oncology, CMH Lahore

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.875

Keywords:

Diabetes, Patients, Health, Morbidity, Mortality

Abstract

Type 2 diabetes mellitus (T2DM) and lung cancer are two prevalent health issues worldwide, each carrying significant morbidity and mortality burdens. Objective: The main objective of the study is to find the effects of type 2 diabetes Type 2 diabetes and its impact on the risk of developing ARDS in patients with lung cancer postoperatively and its prognosis. Methods: This retrospective study was conducted at CMH Lahore from 2021 to 2022. Data were collected from 320 patients diagnosed with lung cancer. Patients diagnosed with lung cancer who underwent surgery were included in the study. Patients with a history of any other malignancies and suffering from COPD were excluded from the study. Electronic medical records were reviewed to collect demographic information, including age, sex, body mass index (BMI), smoking history, comorbidities (including T2DM), tumour characteristics, surgical procedures performed, and postoperative outcomes. Results: Data were collected from 320 diagnosed patients with lung cancer according to inclusion and exclusion criteria. The mean age of the patients was 58.98±5.67 years. There were 60% male and 40% female patients. The prevalence of T2DM was 25%, and 50% followed the lobectomy surgical procedure. 40% of the patients were from stage I, 30% from stage II, 20% from stage III and 10% at stage IV. Forced Expiratory Volume in 1 Second (FEV1) had a mean value of 2.5 litres with a standard deviation of 0.8 litres. Forced Vital Capacity (FVC) showed a mean of 3.0 litres with a standard deviation of 1.0. The FEV1/FVC ratio was approximately 0.83, with a standard deviation of 0.05. Total Lung Capacity (TLC) exhibited a mean value of 5.0 litres with a standard deviation of 1.2 litres. Residual Volume (RV) had a mean of 1.2 litres with a standard deviation of 0.4. Conclusion: It is concluded that type 2 diabetes mellitus (T2DM) is associated with a higher incidence of acute respiratory distress syndrome (ARDS) in lung cancer surgery. T2DM independently predicts lesser prognosis and survival outcomes in patients who develop ARDS postoperatively.

Downloads

Download data is not yet available.

References

Zhang L, Guan L, Tang X, Zhao Y. Effect of type 2 diabetes on the development of acute respiratory distress syndrome (ARDS) in patients with lung cancer after surgery and its prognosis. International Journal of General Medicine. 2023:4573-84.

Giblin MJ, Ontko CD, Penn JS. Effect of cytokine-induced alterations in extracellular matrix composition on diabetic retinopathy-relevant endothelial cell behaviors. Scientific Reports. 2022;12(1):12955.

Zhang R, Chen J, Xiong Y, Wang L, Huang X, Sun T, et al. Increased neutrophil count Is associated with the development of chronic kidney disease in patients with diabetes. Journal of Diabetes. 2022;14(7):442-54.

Cao W, Chen H-D, Yu Y-W, Li N, Chen W-Q. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chinese medical journal. 2021;134(07):783-91.

Ye B, Wang M. Video-assisted thoracoscopic surgery versus thoracotomy for non-small cell lung cancer: a meta-analysis. Combinatorial Chemistry & High Throughput Screening. 2019;22(3):187-93.

Wang C-R, Hu T-Y, Hao F-B, Chen N, Peng Y, Wu J-J, et al. Type 2 Diabetes–Prevention Diet and All-Cause and Cause-Specific Mortality: A Prospective Study. American Journal of Epidemiology. 2022;191(3):472-86.

Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia–a systematic review, meta-analysis, and meta-regression. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14(4):395-403.

Guo J, Liu C, Pan J, Yang J. Relationship between diabetes and risk of gastric cancer: A systematic review and meta-analysis of cohort studies. Diabetes Research and Clinical Practice. 2022;187:109866.

Boyle AJ, Madotto F, Laffey JG, Bellani G, Pham T, Pesenti A, et al. Identifying associations between diabetes and acute respiratory distress syndrome in patients with acute hypoxemic respiratory failure: an analysis of the LUNG SAFE database. Critical Care. 2018;22:1-14.

Sababathy M, Ramanathan G, Abd Rahaman NY, Ramasamy R, Biau FJ, Qi Hao DL, et al. A ‘one stone, two birds’ approach with mesenchymal stem cells for acute respiratory distress syndrome and Type II diabetes mellitus. Regenerative Medicine. 2023;18(12):913-34.

Rezoagli E, McNicholas BA, Madotto F, Pham T, Bellani G, Laffey JG, et al. Presence of comorbidities alters management and worsens outcome of patients with acute respiratory distress syndrome: insights from the LUNG SAFE study. Annals of intensive care. 2022;12(1):42.

Alanazi AH, Almuntashiri S, Sikora A, Zhang D, Somanath PR. Secondary Analysis of Fluids and Catheters Treatment Trial (FACTT) data reveal poor clinical outcomes in acute respiratory distress syndrome patients with diabetes. Respiratory Medicine. 2024;223:107540.

Vassiliou AG, Kotanidou A, Dimopoulou I, Orfanos SE. Endothelial damage in acute respiratory distress syndrome. International journal of molecular sciences. 2020;21(22):8793.

Tang R, Wang H, Peng J, Wang D. A trauma‐related survival predictive model of acute respiratory distress syndrome. Journal of clinical laboratory analysis. 2021;35(11):e24006.

Denson JL, Gillet AS, Zu Y, Brown M, Pham T, Yoshida Y, et al. Metabolic syndrome and acute respiratory distress syndrome in hospitalized patients with COVID-19. JAMA network open. 2021;4(12):e2140568-e.

Battaglini D, Robba C, Pelosi P, Rocco PR. Treatment for acute respiratory distress syndrome in adults: a narrative review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs. 2022;27(2):187-209.

Ramji HF, Hafiz M, Altaq HH, Hussain ST, Chaudry F. Acute respiratory distress syndrome; a review of recent updates and a glance into the future. Diagnostics. 2023;13(9):1528.